Cannabis Investments

Cannabis Science Signs Andrew Pitsicalis as International Brand and Licensing Director, Rockin Artwork Grants Cannabis Science a License to Make Jimi Hendrix Image and Likeness Related Products for Advertising, Manufacturing, Sales and Marketing

Happy 4/20!

April 20, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB: CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to welcome Andrew Pitsicalis as International Brand and Licensing Director.

Mr. Pitsicalis has been CEO of Rockin Artwork since 2010. Rockin Artwork is an intellectual property company, which manages or owns images and art by artists for Licensing and Fine Art. Their works include those by Mike and Dasha Biggs, David Garibaldi, Justin Farano, Dan Kennedy and more. Leon Hendrix, Jimi Hendrix’s brother, is an owner and the spiritual guide of the company and their collection includes Jimi Hendrix images and art for merchandise and licensing.

Rockin Artwork has granted Cannabis Science a co-branding license to allow Cannabis Science to advertise, manufacture, and brand Jimi Hendrix images and likenesses and to make Jimi Hendrix image and likeness related products and the marketing thereof. Leon Hendrix is pleased to endorse Cannabis Sciences’ role in creating great products his brother Jimi Hendrix would be proud of.

When asked his thoughts were joining Cannabis Science Inc., Mr. Pitsicalis said, ”I look forward to creating great quality products. Having experience licensing properties that span a fan base of 2 billion people worldwide, I have licensed products in mass market retail stores around the globe. You can find Pitsicalis’ companies, licensed products in places like, Walmart, Target, Kohls, JC Penny, Urban Outfitters, Old Navy and other mass retail chains.”

Mr. Pitsicalis’s role at Cannabis Science is to help build the brands of Cannabis Science. This will include consulting and brand management of Cannabis Science product lines, manufacture and develop the licensing platform for Cannabis Science, Patents and Trademarks. Mr. Pitsicalis will facilitate the advertising and licensing of products and branding of Cannabis Science. Pitsicalis will be selecting advertising campaigns for brand and product recognition. There are plans in the future to eventually license our biotechnology to pharmaceutical companies and other hemp related manufacturing licenses. Andrew has extensive connections to doctors, intellectual property, and venues for future medical cannabis conferences, all of which are invaluable to Cannabis Science.

Mr. Pitsicalis, legal victories in Federal Court for Jimi Hendrix Intellectual property rights will give Cannabis Science a seasoned component to licensing and branding. Andrew will be seated on the Policy Advisory Board for the company and we are pleased to have his input from his legal and licensing knowledge.

Cannabis Science is excited to welcome another talented and professional individual into the fold and looks forward to the endless promotion opportunities available through Andrew Pitsicalis.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
or
Robert Kane
Investor Relations Management
1-561-234-6929
rkane@cannabisscience.com

View full post on News Releases

Cannabis Science Chief Operating Officer Dr. Moe Afaneh, Pharm D., MBA, NRCC, Confirms Newest Cannabis Science Brand Product Line & Begins Manufacturing and National Distribution Negotiations to Immediately Release The New Product Line

February 24, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB:CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce Dr. Moe Afaneh, Pharm D., MBA, NRCC, RNC has identified the first four Cannabis Science Brand products as the newest line of Cannabis Science Brand of Products. Dr. Afaneh expects to have a full report next week with the new product offering launch plan including nationwide manufacturing and distribution.

The Cannabis Science Executive Team is finalizing negotiations for the manufacturing and national distribution or this new product line. The commercialization process is well underway including securing manufacturing partners that have the resources to support our national distribution and retail outlets such as pharmacies through to grocery outlets and other multi-national retail outlets. Negotiations will actively continue when the first prototypes are received by Cannabis Science to be review by various nationwide product distributors eagerly looking to release this new line of Cannabis Science Brand of Products.

This new product launch is the first mandate for our newly appointed Chief Operations Officer Dr. Afaneh. He has made great progress in the short time since he has begun, and is now ahead of schedule for this launch. Dr. Afaneh’s mandate includes improving the overall efficiency and quality of Cannabis Science’s national pharmaceutical operations and penetrating additional national markets with new developed high quality Cannabis Science brand products. Dr. Afaneh and the Cannabis Science team are working to enter the over-the-counter (OTC) market in 2012, with non-psychoactive nutraceuticals, as well as to enter the dispensary market with both psychoactive and non-psychoactive cannabis-based treatments.

Dr. Robert Melamede, President of Cannabis Science stated, “Dr. Moe is ahead of our projections and we are very proud. The retail availability of these products should increase revenue and that’s great for Cannabis Science and our shareholders. I am confident that we will realize our financial plans and goals that should bring Cannabis Science to profitability in 2014. I look forward to using many of these products for myself and my family in the near future.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science
President & CEO
Dr. Robert Melamede
1.888.889.0888
www.cannabisscience.com
info@cannabisscience.com
or
Investor Relations
Robert Kane
rkane@cannabisscience.com
1.561.234.6929

View full post on News Releases

Cannabis Science Chief Operating Officer Dr. Moe Afaneh, Pharm D., MBA, NRCC, Confirms Newest Cannabis Science Brand Product Line & Begins Manufacturing and National Distribution Negotiations to Immediately Release The New Product Line

February 24, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB:CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce Dr. Moe Afaneh, Pharm D., MBA, NRCC, RNC has identified the first four Cannabis Science Brand products as the newest line of Cannabis Science Brand of Products. Dr. Afaneh expects to have a full report next week with the new product offering launch plan including nationwide manufacturing and distribution.

The Cannabis Science Executive Team is finalizing negotiations for the manufacturing and national distribution or this new product line. The commercialization process is well underway including securing manufacturing partners that have the resources to support our national distribution and retail outlets such as pharmacies through to grocery outlets and other multi-national retail outlets. Negotiations will actively continue when the first prototypes are received by Cannabis Science to be review by various nationwide product distributors eagerly looking to release this new line of Cannabis Science Brand of Products.

This new product launch is the first mandate for our newly appointed Chief Operations Officer Dr. Afaneh. He has made great progress in the short time since he has begun, and is now ahead of schedule for this launch. Dr. Afaneh’s mandate includes improving the overall efficiency and quality of Cannabis Science’s national pharmaceutical operations and penetrating additional national markets with new developed high quality Cannabis Science brand products. Dr. Afaneh and the Cannabis Science team are working to enter the over-the-counter (OTC) market in 2012, with non-psychoactive nutraceuticals, as well as to enter the dispensary market with both psychoactive and non-psychoactive cannabis-based treatments.

Dr. Robert Melamede, President of Cannabis Science stated, “Dr. Moe is ahead of our projections and we are very proud. The retail availability of these products should increase revenue and that’s great for Cannabis Science and our shareholders. I am confident that we will realize our financial plans and goals that should bring Cannabis Science to profitability in 2014. I look forward to using many of these products for myself and my family in the near future.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science
President & CEO
Dr. Robert Melamede
1.888.889.0888
www.cannabisscience.com
info@cannabisscience.com
or
Investor Relations
Robert Kane
rkane@cannabisscience.com
1.561.234.6929

View full post on News Releases

Cannabis Science Chief Operating Officer Dr. Moe Afaneh, Pharm D., MBA, NRCC, Confirms Newest Cannabis Science Brand Product Line & Begins Manufacturing and National Distribution Negotiations to Immediately Release The New Product Line

February 24, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB:CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce Dr. Moe Afaneh, Pharm D., MBA, NRCC, RNC has identified the first four Cannabis Science Brand products as the newest line of Cannabis Science Brand of Products. Dr. Afaneh expects to have a full report next week with the new product offering launch plan including nationwide manufacturing and distribution.

The Cannabis Science Executive Team is finalizing negotiations for the manufacturing and national distribution or this new product line. The commercialization process is well underway including securing manufacturing partners that have the resources to support our national distribution and retail outlets such as pharmacies through to grocery outlets and other multi-national retail outlets. Negotiations will actively continue when the first prototypes are received by Cannabis Science to be review by various nationwide product distributors eagerly looking to release this new line of Cannabis Science Brand of Products.

This new product launch is the first mandate for our newly appointed Chief Operations Officer Dr. Afaneh. He has made great progress in the short time since he has begun, and is now ahead of schedule for this launch. Dr. Afaneh’s mandate includes improving the overall efficiency and quality of Cannabis Science’s national pharmaceutical operations and penetrating additional national markets with new developed high quality Cannabis Science brand products. Dr. Afaneh and the Cannabis Science team are working to enter the over-the-counter (OTC) market in 2012, with non-psychoactive nutraceuticals, as well as to enter the dispensary market with both psychoactive and non-psychoactive cannabis-based treatments.

Dr. Robert Melamede, President of Cannabis Science stated, “Dr. Moe is ahead of our projections and we are very proud. The retail availability of these products should increase revenue and that’s great for Cannabis Science and our shareholders. I am confident that we will realize our financial plans and goals that should bring Cannabis Science to profitability in 2014. I look forward to using many of these products for myself and my family in the near future.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science
President & CEO
Dr. Robert Melamede
1.888.889.0888
www.cannabisscience.com
info@cannabisscience.com
or
Investor Relations
Robert Kane
rkane@cannabisscience.com
1.561.234.6929

View full post on News Releases

Cannabis Science Issues Potential Revenues And Market Data for the New Cannabis Science Brand OTC Products

March 2, 2012

DENVER–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB:CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis and hemp products, issues market data for the four Cannabis Science brand products for the newest over-the-counter line to be released.

The Global Anti-Aging Products Market to reach $291.9 Billion by 2015, and the U. S. Market for Anti-Aging Products for Appearance Enhancement is expected to be more than US$5.0 billion by 2015. The global cosmeceuticals market is US$ 27.2 Billion in 2010 according to a new report by Global Industry Analysts. The US market for skin irritation creams and sunscreen is $6.5 billion. US demand for cosmeceutical products is expected to increase 5.8 percent annually through 2015. The Global Lip Care Products Market is expected to reach $1.7 Billion by 2015. (reportlinker.com NEW YORK, Jan. 11, 2012 /PRNewswire)

Cannabis Science is among the leading experts specializing in developing all natural organic bio healing hemp health, beauty and cosmetics products. Our philosophy is to bring the best products possible to the entire world, to help improve and promote a healthier natural way of life. Superior products are born from scientific data and research and we have come to a new understanding in the keys to our product development.

Dr. Moe Afaneh, Cannabis Science COO, explained, “We believe our sunscreen and protectant is far superior to others, because we have invested time into understanding what occurs in the body and on the skin, and targeting the cascade of events that occurs when people get sunburned. We have meticulously targeted key components that lead to the sunburn and have created our elite formulation so that one instantly feels the skin begin to cool, the pain begins to dissipate and the healing process has begun. We have created our own cascade of healing properties using the finest natural ingredients to mimic our body’s natural pathway when responding to a skin burn.”

Dr. Afaneh added, “Another of our topical skin care products helps provide relief to various skin conditions such as eczema and other recurring skin irritations. We have studied various populations and age groups that suffer from acute and chronic skin irritations. These symptoms varied from raised dry patches of skin, red blotches, hardened patches, mostly appearing in areas of the arms and legs, as well as areas of the body that tended to constantly rub against clothing or other surfaces. Our specialized formulation was designed based on understanding the patients’ expectations from over-the-counter skin care products. By understanding patients’ needs, we created our all natural unique formulation to help improve their quality of life on daily basis. It is designed to help stop the itching and pain, first and foremost, and then begins to lock moisture in and around the area, and then our natural blend of ingredients begins to help the body heal the skin and reduce the irritation.”

Dr. Afaneh concludes with, “Our anti-aging skin serum, specifically formulated for women, helps rejuvenate and soften the skin. The Cannabis Science serum uses only natural ingredients, including hemp oil extract and many other natural oils and ingredients. Our serum leaves the skin looking radiant, energized, softer, healthier, and full of life. Our all-natural lip balm that contains hemp oil extract and our unique blend of ingredients and is unique in that it has natural ingredients that help protect against bacteria and fungus. It also has SPF to protect against the harmful effects of the sun, and is infused with antioxidants and many other natural extracts to soften the lips and lock the moisture in.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
or
Robert Kane
Investor Relations Management
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases